To include your compound in the COVID-19 Resource Center, submit it here.

FDA places holds on blood cancer trials of PD-1/PD-L1, IMiD combos

FDA placed clinical holds on nine blood cancer trials evaluating PD-L1 mAb Imfinzi durvalumab and PD-1 mAb Opdivo nivolumab in combination with immunomodulatory agents (IMiDs). AstraZeneca plc (LSE:AZN; NYSE:AZN), Celgene Corp. (NASDAQ:CELG) and Bristol-Myers Squibb Co. (NYSE:BMY) said

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers